Search Results
Jun 07, 2026, 23:00 ET GIGABYTE、AI駆動技術でマザーボード性能を向上
-- 世界有数のコンピューターブランドであるGIGABYTEは、マザーボードの性能を新たな業界標準へと引き上げ、その技術革新を推進し続けています。Ultra Durable™や性能に重点を置いたSuper Overclocking技術から、AIで強化された最新のD5 Bionic CorsaおよびX3D Turbo Mode 2.0に至るまで、GIGABYTEは技術的課題をAIコンピューティングとゲーミング向けの先進的なイノベーションへと変え続けています。
More news about: GIGABYTE
Jun 07, 2026, 23:00 ET 기가바이트, AI 기반 기술로 메인보드 성능 향상
전용 온보드 하드웨어 칩을 통해 AMD Ryzen™ X3D 프로세서 성능을 극대화하도록 설계된 X3D Turbo Mode 2.0이 있다. 독점 OC 엔진은 방대한 데이터세트로 학습되고 프로세서별 튜닝에 최적화되어 있으며, 온보드 칩은 플랫폼 상태와 시스템 구동 환경을 실시간으로 끊임없이 모니터링한다. 이러한 지능형 하드웨어-소프트웨어 통합은 AI 컴퓨팅, 멀티태스킹, 게이밍 시나리오 등 다양한 구동환경에 지능적으로 대응하는 맞춤형 최적화 성능을 구현한다..기가바이트는 D5 Bionic Corsa 기술을 바탕으로 DDR5 메모리
More news about: GIGABYTE
Jun 07, 2026, 23:00 ET GIGABYTE améliore les performances des cartes mères grâce à des technologies basées sur l'IA
industriel. De la technologie Ultra Durable™ axée sur les performances et le super-overclocking aux dernières innovations telles que le D5 Bionic Corsa optimisé par l'IA et le mode X3D Turbo 2.0, GIGABYTE continue de transformer les défis techniques en innovations de pointe pour l'informatique basée sur l'IA et
More news about: GIGABYTE
Jun 07, 2026, 23:00 ET GIGABYTE nâng tầm hiệu năng bo mạch chủ với các công nghệ ứng dụng AI
Ultra Durable™, công nghệ siêu ép xung Super Overclocking tập trung vào hiệu suất cho đến các công nghệ mới nhất được tăng cường bằng AI như D5 Bionic Corsa và X3D Turbo Mode 2.0, GIGABYTE tiếp tục biến những thách thức kỹ thuật thành các đổi mới hàng đầu dành cho điện toán AI và gaming.
More news about: GIGABYTE
Jun 07, 2026, 21:00 ET 노보네시스, 서울푸드 2026에서 한국 식품업체를 위한 바이오솔루션 선보여
multimedia:https://www.prnewswire.com/kr/news-releases/uB178uBCF4uB124uC2DCuC2A4u002Cu002DuC11CuC6B8uD478uB4DCu002Du0032u0030u0032u0036uC5D0uC11Cu002DuD55CuAD6Du002DuC2DDuD488uC5C5uCCB4uB97Cu002D-302789885.htmlSOURCE
More news about: Novonesis
Jun 07, 2026, 21:00 ET Uhale Adopts Quokka's Q-mast to Strengthen Application Security Testing
vulnerabilities, privacy risks, and compliance gaps earlier in the development process."Security is a continuous process," said Lewis Zhang, R&D General Manager at Uhale. "Adding Q-mast to our workflow is a practical step to strengthen our testing capabilities. It gives us additional visibility
More news about: Uhale
Jun 07, 2026, 21:00 ET GIGABYTE nâng tầm công nghệ màn hình chơi game với hình ảnh được tối ưu bằng AI và bảo vệ OLED tự động
multimedia:https://www.prnewswire.com/vn/news-releases/u0067u0069u0067u0061u0062u0079u0074u0065u002Du006Eu0061u006Eu0067u002Du0074u1EA7u006Du002Du0063u006Fu006Eu0067u002Du006Eu0067u0068u1EC7u002D-302792378.htmlSOURCE
More news about: GIGABYTE
Jun 07, 2026, 20:53 ET Sungrow mở rộng danh mục hệ thống lưu trữ năng lượng (ESS) dân dụng với giải pháp thế hệ mới đảm bảo nguồn điện dự phòng đáng tin cậy
multimedia:https://www.prnewswire.com/vn/news-releases/u0073u0075u006Eu0067u0072u006Fu0077u002Du006Du1EDFu002Du0072u1ED9u006Eu0067u002Du0064u0061u006Eu0068u002Du006Du1EE5u0063u002Du0068u1EC7u002D-302793501.htmlSOURCE
More news about: Sungrow
Jun 07, 2026, 20:08 ET OriCell's GPC3 CAR-T Receives NMPA Clearance for Confirmatory Phase II Trial in Late-Line Advanced Hepatocellular Carcinoma
treatment.Key results:Objective response rate (ORR): 50% across the evaluable population; 66.7% in the recommended Phase II dose (RP2D) cohort; 100% in the highest dose cohort (DL4)Speed of response: 89% of responders had already achieved objective response by their first
More news about: Oricell Therapeutics Holdings Limited
Jun 07, 2026, 20:00 ET Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance
cancer), ALPPL2 x CD3 (ATG-112 for gynecological tumors, digestive system malignancies, bladder cancer and NSCLC), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for multiple myeloma), LILRB4 x CD3 (ATG-102 for acute myeloid leukemia and chronic myelomonocytic leukemia)
More news about: Antengene Corporation Limited
Jun 07, 2026, 17:30 ET Novo Nordisk's CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026
comparators across three phase 3 trials in adults with type 2 diabetes (T2D)1-3Data from the REIMAGINE clinical development program, a series of phase 3 trials evaluating once-weekly CagriSema in adults with T2D across various stages of their disease, were presented at an
More news about: NOVO NORDISK INC.
Jun 07, 2026, 17:30 ET Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications
REIMAGINE 1: CagriSema as Monotherapy for Drug-Naïve T2DVanita R. Aroda, MDSymposium: REIMAGINE 1, 2, 3: Leveraging Amylin and GLP-1 for Type 2 Diabetes Care
More news about: American Diabetes Association
Jun 07, 2026, 10:30 ET MimiSilk Marks 12 Years of Advanced Care with New Product Launches and Anniversary Sale
PDRN Collagen Face Mask—a hydrogel mask formulated with PDRN, 4D Hyaluronic Acid, and Collagen for deep hydration, barrier recovery, and visible skin renewal. Clinically associated with tissue regeneration and collagen
More news about: MimiSilk
Jun 07, 2026, 10:30 ET MimiSilk Marks 12 Years of Advanced Care with New Product Launches and Anniversary Sale
PDRN Collagen Face Mask—a hydrogel mask formulated with PDRN, 4D Hyaluronic Acid, and Collagen for deep hydration, barrier recovery, and visible skin renewal. Clinically associated with tissue regeneration and collagen
More news about: MimiSilk
Jun 07, 2026, 10:30 ET MimiSilk feiert 12 Jahre fortschrittliche Pflege mit neuen Produkten und Jubiläumsverkauf
PDRN Collagen Face Mask vor - eine Hydrogel-Maske mit PDRN, 4D-Hyaluronsäure und Collagen für tiefe Hydratation, Wiederherstellung der Hautbarriere und sichtbare Hauterneuerung. PDRN wird klinisch mit Geweberegeneration
More news about: MimiSilk
Jun 07, 2026, 10:30 ET MimiSilk marque 12 ans de soins avancés avec le lancement de nouveaux produits et une vente anniversaire
PDRN- un masque hydrogel formulé avec du PDRN, de l'acide hyaluronique 4D et du collagène pour une hydratation en profondeur, une récupération de la barrière cutanée et un renouvellement visible de la peau. Cliniquement associé
More news about: MimiSilk
Jun 07, 2026, 10:30 ET MimiSilk celebra 12 años de cuidado avanzado con lanzamientos de nuevos productos y rebajas de aniversario
mascarilla facial de colágeno PDRN: una mascarilla de hidrogel formulada con PDRN, ácido hialurónico 4D y colágeno para una hidratación profunda, la recuperación de la barrera cutánea y una renovación visible de la piel. Clínicamente asociado con la regeneración
More news about: MimiSilk
Jun 07, 2026, 08:00 ET Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk unveils new data at ADA 2026
States, Novo Nordisk has a 40-year presence, is headquartered in New Jersey and employs approximately 10,000 people across more than 10 manufacturing, R&D, and corporate locations in seven states plus Washington, D.C. For more information, visit
More news about: NOVO NORDISK INC.
Jun 07, 2026, 07:14 ET 世界環境デーに、持続可能性を成果につなげる：工場から家庭まで、水とエネルギーの消費削減に取り組むBeko
hi*、Voltas Beko、Singer*、ElektraBregenz、Flavel、Bauknecht、Privileg、Altus、Ignis、Polar）を所有し、または限定ライセンスに基づいて使用しています。Bekoは、市場シェア（数量ベース）で欧州最大の白物家電企業であり、2025年の連結売上高は107億ユーロに達しました。世界各地にあるBekoのR&D・デザインセンターおよびオフィス28か所には、2,000人を超えるR&D担当従業員が在籍しており、国際登録特許出願件数はこれまでに4,500件を超えています。同社は、S&P
More news about: Beko
Jun 06, 2026, 22:30 ET CERAVE TÔN VINH HƠN 100 NHÀ SÁNG TẠO NỘI DUNG TỪNG GIÀNH GIẢI THƯỞNG TỪ 22 QUỐC GIA TRONG CUỘC THI CERAWARDS TOÀN CẦU ĐẦU TIÊN
multimedia:https://www.prnewswire.com/vn/news-releases/u0063u0065u0072u0061u0076u0065u002Du0074u006Fu006Eu002Du0076u0069u006Eu0068u002Du0068u01A1u006Eu002Du0031u0030u0030u002Du006Eu0068u0061u002D-302793342.htmlSOURCE
More news about: CeraVe
Jun 06, 2026, 21:52 ET A New Era Begins: Cal Poly Unveils the John Madden Football Center
the student-athlete experience because he lived it — playing both football and baseball at Cal Poly," said university President Jeffrey D. Armstrong. "That perspective fueled his commitment to our players, their Learn by Doing experience, and a standard of excellence that drives success
More news about: Cal Poly in San Luis Obispo
Jun 06, 2026, 20:27 ET 전 세계 출산 지연 및 난임 증가로 국경 간 난임 치료 수요 확대
multimedia:https://www.prnewswire.com/kr/news-releases/uC804u002DuC138uACC4u002DuCD9CuC0B0u002DuC9C0uC5F0u002DuBC0Fu002DuB09CuC784u002DuC99DuAC00uB85Cu002DuAD6DuACBDu002DuAC04u002DuB09CuC784u002D-302793336.htmlSOURCE
More news about: TFC Taipei Fertility Center
Jun 06, 2026, 14:30 ET Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity
Patients with T2D (TRANSCEND-T2D-1)Harpreet Singh Bajaj, MD, MPHSymposium: Unlocking the Next Frontier in Treatment of Obesity and Type 2 Diabetes with Retatrutide: A Triple Agonist, Activating the GIP, GLP-1 and Glucagon Receptors (TRANSCEND-T2D-1 and TRIUMPH-1
More news about: American Diabetes Association
Jun 06, 2026, 14:30 ET Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
enrolled more than 5,800 participants with additional results anticipated over the next year.About TRANSCEND-T2D-1 and the TRANSCEND-T2D clinical trial programTRANSCEND-T2D-1 (NCT06354660) is a Phase 3, 40-week, randomized, double-blind, placebo-controlled study comparing the efficacy
More news about: Eli Lilly and Company
Jun 06, 2026, 13:17 ET 세라비, 제1회 글로벌 세라워즈에서 22개국 100여 명의 수상 경력 콘텐츠 크리에이터 기념
multimedia:https://www.prnewswire.com/kr/news-releases/uC138uB77CuBE44u002Cu002DuC81Cu0031uD68Cu002DuAE00uB85CuBC8Cu002DuC138uB77CuC6CCuC988uC5D0uC11Cu002Du0032u0032uAC1CuAD6Du002Du0031u0030u0030-302793284.htmlSOURCE
More news about: CeraVe